Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population

TURKOVAC™ is a whole-virion inactivated COVID-19 vaccine which was developed and granted emergency use and conditional marketing authorization in December 2021 in Türkiye. The objective of this study is to assess the distribution and the severity of allergic adverse events following the administration of the vaccine as the primary or the booster dose in 15 provinces in Türkiye. In this cohort study, between February and May 2022, in the selected 15 provinces having an adequate number of health care personnel in the community health centers to conduct the study, 32,300 people having the first, the second, or the booster dose of the vaccine were invited to the survey. A total of 29,584 people voluntarily agreed to participate to the survey and were given a structured questionnaire after a minimum of 10 days following the vaccination. In our study, only 0.5% of the participants (142 persons) reported to experience any allergic reaction, and 12 of them (8.5%) reported to be given medical treatment in a health center. Male predominance (55.6%) was observed among participants reported to experience any allergic reaction. No hospitalization was recorded. Of the participants, 4.4% (1315 people) reported to have a history of allergy. The most reported allergens were drugs. Among the participants without a known history of allergy (n = 28,269), 0.4% of them (110 people) reported to experience an allergic reaction following the vaccination, and 5.4% of the allergic reactions (six people) were reported to be treated in a health center. The percentage of the participants given any medical treatment among the participants without a known history of allergy is 0.02%. No immediate or anaphylactic reaction was reported. Among the participants with a known history of allergy (n = 1315), 32 people (2.4% of them) reported to experience an allergic reaction following the vaccination, and 18.7% of the allergic reactions (six people) were reported to be prescribed a medical treatment. The percentage of the participants given any medical treatment among the participants with a known history of allergy is 0.4%. A known history of allergy increased the risk of having an allergic experience by approximately six times following vaccination. As a whole-virion inactivated SARS-CoV-2 vaccine, the TURKOVAC™ vaccine, with a low allergic reaction-related adverse event profile, can be an alternative to other COVID-19 vaccines.

[1]  I. Çelik,et al.  Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial , 2022, Vaccines.

[2]  A. Kara,et al.  Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials , 2022, Vaccine.

[3]  G. Reyes-Terán,et al.  Anaphylaxis to SARS-CoV-2 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program , 2022, Journal of Clinical Immunology.

[4]  O. Watson,et al.  Global impact of the first year of COVID-19 vaccination: a mathematical modelling study , 2022, The Lancet Infectious Diseases.

[5]  K. Guan,et al.  Allergic Reactions After the Administration of COVID-19 Vaccines , 2022, Frontiers in Public Health.

[6]  M. Taha,et al.  Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors , 2022, Vaccines.

[7]  C. Janson,et al.  Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper , 2022, Allergy.

[8]  Manfred S. Green,et al.  Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine , 2022, Vaccines.

[9]  K. Dhama,et al.  Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis , 2021, Allergy, Asthma & Clinical Immunology.

[10]  Zhiguo Wang,et al.  The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015–2018 , 2021, BMC Public Health.

[11]  H. Larson,et al.  Vaccine Hesitancy: Drivers and How the Allergy Community Can Help , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[12]  J. Bernstein,et al.  The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[13]  T. Tung,et al.  Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China , 2021, Expert review of vaccines.

[14]  T. Shimabukuro Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021 , 2021, American Journal of Transplantation.

[15]  T. Shimabukuro Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020 , 2021, American Journal of Transplantation.

[16]  S. Vieths,et al.  Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives , 2021, Allergy.

[17]  A. Muraro,et al.  COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee , 2021, World Allergy Organization Journal.

[18]  anonymous,et al.  Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[19]  T. Shimabukuro,et al.  Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[20]  F. Destefano,et al.  Vaccine‐associated hypersensitivity , 2018, The Journal of allergy and clinical immunology.

[21]  W. Jiskoot,et al.  Vaccines , 2013, Reactions Weekly.

[22]  A Staines,et al.  Emerging advantages and drawbacks of telephone surveying in public health research in Ireland and the U.K , 2006, BMC public health.

[23]  Michael Schwenk,et al.  Anaphylaxis , 1919, The Indian medical gazette.